natgillin/translations-raw huggingface dataset:
The difference in the proportion of patients who maintained < 400 copies/ml at week 48 was mainly influenced by the higher number of discontinuations in the tenofovir disoproxil treatment group.
Na razliko v deležu bolnikov, ki so ohranili < 400 kopij/ml v 48. tednu, je v glavnem vplivalo večje število prekinitev v skupini zdravljenja z dizoproksiltenofoviratom.
Administration of tenofovir disoproxil with a high fat meal enhanced the oral bioavailability, with an increase in tenofovir AUC by approximately 40% and Cmax by approximately 14%.
Jemanje dizoproksiltenofovirata z maščobami bogatim obrokom je povečalo peroralno biološko razpoložljivost s povečanjem AUC tenofovirja za približno 40% in Cmax za približno 14%.
Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Bolniki z redko dedno intoleranco za galaktozo, odsotnostjo encima laktaze ali malabsorpcijo glukoze/galaktoze ne smejo jemati tega zdravila.
Following intravenous administration the steady-state volume of distribution of tenofovir was estimated to be approximately 800 ml/kg.
Po intravenoznem odmerku je volumen porazdelitve tenofovirja v stanju dinamičnega ravnotežja znašal po ocenah približno 800 ml/kg.
If overdose occurs the patient must be monitored for evidence of toxicity (see sections 4.8 and 5.3), and standard supportive treatment applied as necessary.
V primeru prevelikega odmerka je potrebno pri bolniku nadzorovati znake toksičnosti (glejte poglavji 4.8 in 5.3) in mu nuditi standardno podporno zdravljenje.
The bottle contains 30 film-coated tablets and a silica gel desiccant (in a container).
Plastenka vsebuje 30 filmsko obloženih tablet in silikagelsko sušilno sredstvo (v vsebniku).
Efavirenz or lamivudine resistance either preceded or was coincident with the development of K65R in all cases.
V vseh primerih je bila rezistenca na efavirenz oziroma lamivudin ali predhodno obstoječa ali pa sočasna z razvojem K65R.
In other studies (prospective and cross-sectional), the most pronounced decreases in BMD were seen in patients treated with tenofovir disoproxil as part of a regimen containing a boosted protease inhibitor.
V drugih študijah (prospektivne in presečne) so najbolj izrazito zmanjšanje MGK opazili pri bolnikih, zdravljenih z dizoproksiltenofoviratom kot del režima, ki je vseboval okrepljen zaviralec proteaze.
Interactions between tenofovir disoproxil and other medicinal products are listed in Table 1 below (increase is indicated as “↑”, decrease as “↓”, no change as “↔”, twice daily as “b.i.d.”, and once daily as “q.d.”).
Interakcije med dizoproksiltenofoviratom in drugimi zdravili so navedene v preglednici 1 spodaj (povečanje je označeno z znakom “↑”, zmanjšanje z “↓”, brez spremembe z “↔”, dvakrat na dan z “b.i.d.”, enkrat na dan pa s “q.d.”).
If you miss a dose of Tenofovir disoproxil Zentiva, work out how long since you should have taken it.
Če ste izpustili odmerek zdravila Dizoproksiltenofovirat Zentiva, izračunajte, koliko časa je minilo od takrat, ko bi ga morali vzeti.
The European Medicines Agency has deferred the obligation to submit the results of studies with tenofovir disoproxil in one or more subsets of the paediatric population in HIV and chronic hepatitis B (see section 4.2 for information on paediatric use).
Evropska agencija za zdravila je začasno odložila zahtevo za predložitev rezultatov študij z zdravilom Dizoproksiltenofovirat za eno ali več podskupin pediatrične populacije za virus HIV in kronični hepatitis B (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Patients with liver disease including chronic hepatitis B or C, who are treated with antiretrovirals, have a higher risk of severe and potentially fatal liver complications.
Pri bolnikih z jetrnimi boleznimi, vključno s kroničnim hepatitisom B ali C, ki se zdravijo s protiretrovirusnimi zdravili, obstaja povečano tveganje za pojav hudih in potencialno usodnih zapletov.
MARKETING AUTHORISATION NUMBER(S) EU/1/16/1127/001
ŠTEVILKA (ŠTEVILKE) DOVOLJENJA (DOVOLJENJ) ZA PROMET Z ZDRAVILOM EU/1/16/1127/001
• HIV adolescent educational brochure • HBV adolescent educational brochure
• izobraževalno gradivo o mladostnikih s HIV • izobraževalno gradivo o mladostnikih s HBV
There is insufficient information on the effects of tenofovir in newborns/infants.
Podatki o učinku tenofovirja na dojene novorojence/otroke so nezadostni.
If you think that you may have any of these serious side effects, talk to your doctor.
Če menite, da bi lahko imeli katerega koli od teh resnih neželenih učinkov, se posvetujte s svojim zdravnikom.
Look out for signs of inflammation or infection soon after you start taking Tenofovir disoproxil Zentiva.
Bodite pozorni na simptome vnetja ali okužbe kmalu po začetku jemanja zdravila Dizoproksiltenofovirat Zentiva.
Entecavir (0.5 mg or 1 mg) n = 22
entekavir (0,5 mg ali 1 mg) n = 22
ALT elevations had a median time to onset of 8 weeks, resolved with continued treatment, and, in a majority of cases, were associated with a ≥ 2 log10 copies/ml reduction in viral load that preceded or coincided with the ALT elevation.
Mediana časa do zvišanja ALT med zdravljenjem je bila 8 tednov, zvišanje se je ob neprekinjenem zdravljenju prenehalo, v večini primerov pa je bilo povezano z zmanjšanjem virusne obremenitve za ≥ 2 log10 kopij/ml, ki se je zgodilo pred zvišanjem ALT ali pa je sovpadalo z njim.
Tenofovir is primarily excreted by the kidney by both filtration and an active tubular transport system with approximately 70 - 80% of the dose excreted unchanged in urine following intravenous administration.
Tenofovir se primarno izloča preko ledvic tako s filtracijo kot z aktivnim tubularnim transportnim sistemom, pri čemer se po intravenoznem vnosu približno 70-80% odmerka izloči nespremenjenega s sečem.
Some patients have had blood tests or symptoms indicating that their hepatitis has got worse after stopping Tenofovir disoproxil Zentiva.
Krvne preiskave ali simptomi pri nekaterih bolnikih so kazali, da se je njihov hepatitis poslabšal po prenehanju zdravljenja z zdravilom Dizoproksiltenofovirat Zentiva.
Appropriate precautions must continue to be used.
Zato morate še naprej uporabljati ustrezne zaščitne ukrepe.
Tenofovir disoproxil must be taken with food, as food enhances the bioavailability of tenofovir (see section
Dizoproksiltenofovirat se mora jemati s hrano, kajti hrana poviša biološko razpoložljivost tenofovirja (glejte poglavje 5.2).
Data pertaining to HIV
Informacije, ki se nanašajo na virus HIV
Therapy should be initiated by a physician experienced in the management of HIV infection and/or treatment of chronic hepatitis B.
Terapijo mora izvajati zdravnik, ki že ima izkušnje z zdravljenjem okužbe z virusom HIV in/ali z zdravljenjem kroničnega hepatitisa B.
Histological response a,b a The population used for analysis of histology included only patients with available liver biopsy data (Missing = Excluded) by week 240.
Histološki odziva,b (%) a V populaciji, ki so jo uporabili za histološko analizo, so bili samo bolniki, za katere so bili na voljo podatki o biopsiji jeter (manjkajoči = izključeni) do 240. tedna.
Exacerbations of hepatitis during treatment
Poslabšanja hepatitisa med zdravljenjem
Effects on drug levels Mean percent change in AUC, Cmax, Cmin
Učinki na koncentracije učinkovin Srednja sprememba AUC, Cmax, Cmin v odstotkih
As a general rule, it is recommended that HIV and HBV infected women do not breast-feed their infants in order to avoid transmission of HIV and HBV to the infant.
Splošno priporočljivo je, naj s HIV in HBV okužene ženske ne dojijo, da se prepreči prenos HIV in HBV na dojenčka.
Method of administration Tenofovir disoproxil Zentiva tablets should be taken once daily, orally with food.
Način uporabe Tablete Dizoproksiltenofovirat Zentiva se jemljejo enkrat dnevno, peroralno s hrano.
- In HBeAg negative patients without cirrhosis, treatment should be administered at least until HBs seroconversion or there is evidence of loss of efficacy.
- Pri HBeAg negativnih bolnikih brez ciroze naj zdravljenje traja najmanj do HBs serološke konverzije ali do dokazane izgube učinkovitosti.
Tenofovir shows activity in vitro against HIV-2, with an EC50 of 4.9 µmol/l in MT-4 cells.
Tenofovir kaže in vitro aktivnost proti HIV-2 z EC50 4,9 μmol/l v MT-4 celicah.
Age Pharmacokinetic studies have not been performed in the elderly (over 65 years of age).
Starost Farmakokinetične študije niso bile izvedene pri starejših (nad 65 let).
Tenofovir is principally eliminated via the kidney.
Tenofovir se v glavnem izloča preko ledvic.
Animal studies do not indicate harmful effects of tenofovir disoproxil on fertility.
Študije na živalih ne kažejo škodljivih učinkov dizoproksiltenofovirata na plodnost.
Bone toxicity was diagnosed as osteomalacia (monkeys) and reduced bone mineral density (BMD) (rats and dogs).
Toksičen vpliv na kosti je bil diagnosticiran kot osteomalacija (pri opicah) in kot zmanjšana mineralna gostota kosti (MGK) (podgane in psi).
The pharmacokinetics of tenofovir in paediatric patients with renal impairment have not been studied.
Farmakokinetike tenofovira pri pediatričnih bolnikih z ledvično okvaro niso preučili.
The silica gel desiccant is contained in a separate container and should not be swallowed.
Silikagelsko sušilno sredstvo je v posebni vrečici ali vsebniku, ki ga ne smete zaužiti.
• If you are an adult and have problems with your kidneys, your doctor may advise you to take Tenofovir disoproxil Zentiva less frequently.
• Če ste odrasla oseba in imate ledvične težave, vam bo zdravnik morda svetoval, da jemljete zdravilo Dizoproksiltenofovirat Zentiva manj pogosto.
It is not considered to be causally associated with tenofovir disoproxil in the absence of this condition.
Ne obravnava se kot občasno povezan z dizoproksiltenofoviratom v odsotnosti tega stanja.
The breakdown of muscle, softening of the bones (with bone pain and sometimes resulting in fractures), muscle pain, muscle weakness and decreases in potassium or phosphate in the blood may occur due to damage to kidney tubule cells.
Razpad mišičnega tkiva, mehčanje kosti (z bolečinami v kosteh, včasih tudi zlom), bolečine v mišicah, mišična oslabelost in zmanjšanje količine kalija ali fosfatov v krvi se lahko pojavijo zaradi okvare celic ledvičnih tubulov.
Film-coated tablet
Filmsko obložena tableta.
Resistance: No HBV mutations associated with tenofovir disoproxil resistance have been identified (see Clinical efficacy and safety).
Rezistenca: Mutacij virusa HBV, povezanih z rezistenco na dizoproksiltenofovirat, niso odkrili (glejte razdelek Klinična učinkovitost in varnost).
Although there are limited clinical data on the use of Tenofovir disoproxil Zentiva in pregnant women, it is not usually used unless absolutely necessary.
Čeprav so na voljo nezadostni klinični podatki o uporabi zdravila Dizoproksiltenofovirat Zentiva pri nosečnicah, se zdravila Dizoproksiltenofovirat Zentiva ponavadi ne uporablja, razen če je nujno potrebno.
Tenofovir has been shown to be excreted in human milk.
Pokazalo se je, da se tenofovir izloča v materino mleko.
abdominal pain, abdominal distension, flatulence
abdominalna bolečina, napenjanje, flatulenca
The benefits of long-term virologic suppression with continued therapy must be weighed against the risk of prolonged treatment, including the emergence of resistant hepatitis B virus and the uncertainties as regards the long term impact of bone and renal toxicity (see section 4.4).
Koristi dolgotrajne virološke supresije z nadaljevanjem zdravljenja je treba pretehtati glede na tveganje podaljšanega zdravljenja, vključno s pojavom rezistentnega virusa hepatitisa B in negotovostmi v povezavi z dolgoročnimi toksičnimi učinki na kosti in ledvice (glejte poglavje 4.4).
Tenofovir disoproxil Zentiva is available only as 245 mg film-coated tablets, it is not suitable for the use in paediatric patients aged 2 < 12 years.
Zdravilo Dizoproksiltenofovirat Zentiva je na voljo samo v obliki 245 mg filmsko obloženih tablet, zato ni primerno za uporabo pri pediatričnih bolnikih, starih 2 do < 12 let.
Patients with pre-existing liver dysfunction including chronic active hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy (CART) and should be monitored according to standard practice.
Bolniki s predobstoječo jetrno disfunkcijo, vključno s kroničnim aktivnim hepatitisom, imajo v času kombinirane protiretrovirusne terapije (CART, combination antiretroviral therapy) več anomalij jetrne funkcije in jih je treba nadzirati v skladu s standardno prakso.
Tenofovir disoproxil at a concentration of 100 µmol/l had no effect on any of the CYP450 isoforms, except CYP1A1/2, where a small (6%) but statistically significant reduction in metabolism of CYP1A1/2 substrate was observed.
Dizoproksiltenofovirat ni imel pri koncentraciji 100 μmol/l nobenega vpliva na katero koli obliko CYP450 izoformov, izjema je CYP1A1/2, kjer so opazili majhno (6%) toda statistično pomembno zmanjšanje presnove substrata za CYP1A1/2.
Due to limitations of the study, a benefit of tenofovir disoproxil over placebo was not demonstrated based on plasma HIV-1 RNA levels at week 24.
Zaradi omejitev študije koristi dizoproksiltenofovirata v primerjavi s placebom v 24. tednu na podlagi ravni plazemski HIV-1 RNA niso dokazali.
The use of tenofovir disoproxil may be considered during pregnancy, if necessary.
Če je potrebno, se lahko pretehta možnost uporabe dizoproksiltenofovirata med nosečnostjo.
Findings in the rat and monkey studies indicated that there was a substancerelated decrease in intestinal absorption of phosphate with potential secondary reduction in BMD.
Rezultati študij izvedenih na podganah in opicah so pokazala z učinkovino povezano zmanjšanje absorpcije fosfata v črevesju s potencialno sekundarnim zmanjšanjem MGK.
Findings in repeated dose toxicity studies in rats, dogs and monkeys at exposure levels greater than or equal to clinical exposure levels and with possible relevance to clinical use include renal and bone toxicity and a decrease in serum phosphate concentration.
Ugotovitve iz študij toksičnosti pri ponavljajočih se odmerkih pri podganah, psih in opicah pri stopnjah izpostavljenosti, ki so bile večje ali enake stopnjam klinične izpostavljenosti, in ki so morda pomembne za klinično uporabo, vključujejo toksičen vpliv na ledvice in kosti in zmanjšanje koncentracije serumskega fosfata.
• adults
• odrasle
If you have hepatitis B or HIV and hepatitis B together (co-infection), it is very important not to stop your Tenofovir disoproxil Zentiva treatment without talking to your doctor first.
Če ste okuženi s hepatitisom B ali sočasno okuženi z virusom HIV in hepatitisom B, je zelo pomembno, da ne prenehate z zdravljenjem z zdravilom Dizoproksiltenofovirat Zentiva, ne da bi se prej posvetovali z zdravnikom.
Patients with cirrhosis may be at a higher risk for hepatic decompensation following hepatitis exacerbation, and therefore should be monitored closely during therapy.
Bolniki s cirozo so lahko bolj izpostavljeni tveganju za jetrno dekompenzacijo po poslabšanju hepatitisa, zato jih je treba med zdravljenjem skrbno nadzorovati.
Based on the results of in vitro experiments and the known elimination pathway of tenofovir, the potential for CYP450 mediated interactions involving tenofovir with other medicinal products is low.
Na osnovi rezultatov z in vitro preizkusov in glede na znano pot izločanja tenofovirja je možnost za s CYP450 posredovano interakcijo tenofovirja z drugimi zdravili majhna.
hepatic steatosis, hepatitis Skin and subcutaneous tissue disorders: Very common:
jetrna steatoza, hepatitis Bolezni kože in podkožja: Zelo pogosti:
Your doctor may order blood tests during treatment to monitor how your kidneys work.
Vaš zdravnik bo morda naredil krvne preiskave v času zdravljenja, da bo nadzoroval delovanje vaših ledvic.
Tenofovir pharmacokinetics were not substantially altered in subjects with hepatic impairment suggesting that no dose adjustment is required in these subjects.
Farmakokinetika tenofovirja se pri osebah z motnjami v delovanju jeter ni bistveno spremenila, kar nakazuje, da pri teh osebah ni potrebno prilagoditi odmerjanja.
Studies have established the pathway of active tubular secretion of tenofovir to be influx into proximal tubule cell by the human organic anion transporters (hOAT) 1 and 3 and efflux into the urine by the multidrug resistant protein 4 (MRP 4).
V študijah so ugotovili, da pri aktivni tubularni sekreciji tenofovir vstopa v celice proksimalnih tubulov preko prenašalcev hOAT (human organic anion transporter) 1 in 3, v urin pa izstopa preko beljakovine MRP 4 (multidrug resistant protein 4).
Baseline genotypic analysis of HIV isolates from 253 patients revealed that 94% of patients had HIV-1 resistance mutations associated with nucleoside reverse transcriptase inhibitors, 58% had mutations associated with protease inhibitors and 48% had mutations associated with non-nucleoside reverse transcriptase inhibitors.
Genotipska analiza HIV izolatov pri 253 bolnikih je ob začetku študije odkrila, da ima 94% bolnikov HIV-1 mutacije za rezistenco povezane z nukleozidnimi zaviralci reverzne transkriptaze, 58% je imelo mutacije, povezane s proteaznimi zaviralci, in 48% je imelo mutacije, povezane z nenukleozidnimi zaviralci reverzne transkriptaze.
If you take more Tenofovir disoproxil Zentiva than you should If you accidentally take too many Tenofovir disoproxil Zentiva tablets, you may be at increased risk of experiencing possible side effects with this medicine (see section 4, Possible side effects).
Če ste vzeli večji odmerek Dizoproksiltenofovirat Zentiva, kot bi smeli Če ste pomotoma zaužili preveč tablet zdravila Dizoproksiltenofovirat Zentiva, se lahko poveča tveganje pojava možnih neželenih učinkov povezanih s tem zdravilom (glejte poglavje 4, Možni neželeni učinki).
Moderate renal impairment (creatinine clearance 30 - 49 ml/min) If administration of a lower dose is not possible, prolonged dose intervals using the 245 mg film-coated tablets may be used.
Zmerna ledvična okvara (očistek kreatinina od 30-49 ml/min) Če dajanje nižjega odmerka ni mogoče, se lahko uporabijo podaljšani odmerni intervali z 245 mg filmsko obložene tablete.
In exceptional circumstances in patients having particular difficulty in swallowing, Tenofovir disoproxil Zentiva can be administered following disintegration of the tablet in at least 100 ml of water, orange juice or grape juice.
V izjemnih primerih, pri bolnikih, ki imajo posebne težave pri požiranju, pa se lahko zdravilo Dizoproksiltenofovirat Zentiva zaužije razdrobljeno v najmanj 100 ml vode, pomarančnega ali grozdnega soka.
It is recommended that creatinine clearance is calculated in all patients prior to initiating therapy with tenofovir disoproxil and renal function (creatinine clearance and serum phosphate) is also monitored after two to four weeks of treatment, after three months of treatment and every three to six months thereafter in patients without renal risk factors.
Pred začetkom zdravljenja z dizoproksiltenofoviratom se priporoča izračun očistka kreatinina pri vseh bolnikih in nadzor delovanja ledvic (očistek kreatinina in koncentracija serumskega fosfata) po dveh do štirih tednih zdravljenja, po treh mesecih zdravljenja in zatem vsake tri do šest mesecev pri bolnikih brez dejavnikov tveganja za ledvice.
Co-infection with hepatitis C or D: There are no data on the efficacy of tenofovir in patients co-infected with hepatitis C or D virus.
Sočasna okužba s hepatitisom C ali D: Podatkov o učinkovitosti tenofovirja pri bolnikih s sočasno okužbo z virusom hepatitisa C ali D ni.
Reductions in BMD have been reported in paediatric patients.
Poročali so o zmanjšanju MGK pri pediatričnih bolnikih.
One patient in the tenofovir disoproxil arm developed the K70E substitution in the virus.
Pri enem bolniku v skupini z dizoproksiltenofoviratom se je pri virusu razvila substitucija K70E.
No data are available on which to make a dose recommendation for patients over the age of 65 years (see section 4.4).
Podatkov, na osnovi katerih bi lahko priporočili odmerke za bolnike starejše od 65 let, ni na voljo (glejte poglavje 4.4).
If you notice signs of inflammation or infection, tell your doctor at once.
Če opazite simptome vnetja ali okužbe, o tem nemudoma obvestite zdravnika.
If you have particular difficulty swallowing, you can use the tip of a spoon to crush the tablet.
Če imate težave s pogoltnjenjem, lahko tableto zdrobite s konico žlice.
Based on these data, it is unlikely that clinically significant interactions involving tenofovir disoproxil and medicinal products metabolised by CYP450 would occur.
Na podlagi teh podatkov ni verjetno, da bi prišlo do klinično pomembnih interakcij med dizoproksiltenofoviratom in zdravili, ki jih presnavlja CYP450.
Animal studies do not indicate reproductive toxicity (see section 5.3).
Študije na živalih ne kažejo na vpliv na sposobnost razmnoževanja (glejte poglavje 5.3).
Oblong-shaped, light blue colored film-coated tablets with dimensions approx. 17.2 x 8.2 mm.
Podolgovate, svetlo modro obarvane filmsko obložene tablete velikosti približno 17,2 x 8,2 mm.
Co-infection with HIV-1 and hepatitis B: Due to the risk of development of HIV resistance, tenofovir disoproxil should only be used as part of an appropriate antiretroviral combination regimen in HIV/HBV co-infected patients.
Sočasna okužba z virusom HIV-1 in virusom hepatitisa B: Zaradi tveganja za nastanek odpornosti virusa HIV se sme dizoproksiltenofovirat pri bolnikih, okuženih z virusoma HIV/HBV, uporabljati samo kot del ustreznega režima kombiniranega protiretrovirusnega zdravljenja.
In vitro protein binding of tenofovir to plasma or serum protein was less than 0.7 and 7.2%, respectively, over the tenofovir concentration range 0.01 to 25 µg/ml.
In vitro je bila vezava tenofovirja na plazemske proteine manjša od 0,7% oziroma na serumske proteine manjša od 7,2% v koncentracijskem območju tenofovirja od 0,01 do 25 μg/ml.
The EC50 values for tenofovir were in the range of 0.14 to 1.5 µmol/l, with CC50 (50% cytotoxicity concentration) values > 100 µmol/l.
Vrednosti EC50 za tenofovir so bile v razponu od 0,14 do 1,5 μmol/l, vrednosti CC50 (50% citotoksične koncentracije) pa so bile > 100 μmol/l.
BMD Z-scores were not adjusted for height and weight.
Zindeksi MGK niso bili prilagojeni telesni višini in masi.
• It is also important to tell your doctor if you are taking ledipasvir/sofosbuvir, sofosbuvir/velpatasvir or sofosbuvir/velpatasvir/voxilaprevir to treat hepatitis C infection.
• Prav tako je pomembno, da svojemu osebnemu zdravniku poveste, če jemljete ledipasvir/sofosbuvir, sofosbuvir/velpatasvir ali sofosbuvir/velpatasvir/voksilaprevir za zdravljenje okužbe s hepatitisom C.
n (%)a
n (%)
However, administration of tenofovir disoproxil with a light meal did not have a significant effect on the pharmacokinetics of tenofovir.
Vendar pa jemanje dizoproksiltenofovirata z lažjim obrokom ni imelo bistvenega vpliva na farmakokinetiko tenofovirja.
HIV-1 and hepatitis B: In patients receiving tenofovir disoproxil, rare events of renal impairment, renal failure and uncommon events of proximal renal tubulopathy (including Fanconi syndrome) sometimes leading to bone abnormalities (infrequently contributing to fractures) have been reported.
HIV-1 in hepatitis B: Pri bolnikih, ki so prejemali dizoproksiltenofovirat so poročali o redkih dogodkih ledvične okvare, ledvične odpovedi in občasnih dogodkih proksimalne ledvične tubulopatije (vključno s Fanconijevim sindromom), ki včasih vodijo k anomalijam na kosteh (redko prispevajo k zlomom).
Tenofovir disoproxil Zentiva is not suitable for the following groups:
Zdravilo Dizoproksiltenofovirat Zentiva ni primerno za naslednje skupine: